Psyence Biomedical Ltd.

Contributing Author

Recent Articles by Psyence Biomedical Ltd.

Dec-19	Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial PBM -31.51% GlobeNewswire
Dec-09	Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science PBM GlobeNewswire
Nov-25	Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program PBM GlobeNewswire
Nov-20	Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets PBM GlobeNewswire
Nov-12	Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs PBM GlobeNewswire
Nov-06	Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care PBM GlobeNewswire
Nov-03	Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment PBM GlobeNewswire
Aug-28	Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025 PBM GlobeNewswire
Aug-04	Corporate Update, August 2025 PBM GlobeNewswire
Jul-31	Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production PBM GlobeNewswire